X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22

    Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

    Full service: the expertise and efficiency of a one-stop shop

    Full service: the expertise and efficiency of a one-stop shop

    UCB and Microsoft expand drug development partnership

    UCB and Microsoft expand drug development partnership

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

    Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

    AstraZeneca and IDT Biologika sign LOI to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22

    Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

    Full service: the expertise and efficiency of a one-stop shop

    Full service: the expertise and efficiency of a one-stop shop

    UCB and Microsoft expand drug development partnership

    UCB and Microsoft expand drug development partnership

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

    Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

    AstraZeneca and IDT Biologika sign LOI to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

UCB and Microsoft expand drug development partnership

Content Team by Content Team
25th February 2021
in Drug Development, News
UCB and Microsoft expand drug development partnership

UCB and Microsoft have entered into a new multi-year, strategic collaboration. The collaboration will merge Microsoft’s computational services, Cloud and artificial intelligence (AI) with UCB’s drug discovery and development capabilities.

With this latest deal, the companies intend to rapidly discover and develop therapies for people with severe immunological and neurological diseases.

As many drug discovery activities need high-dimensional data set or multi-modal unstructured information analysis, Microsoft’s platform can aid UCB scientists, including data scientists, in discovering novel treatments efficiently and innovatively.

UCB CEO Jean-Christophe Tellier said: “We are delighted to be collaborating with Microsoft to uncover new insights to better understand a patient’s condition, as well as the science, and to enable an enhanced patient experience.

“By amplifying the power of scientific innovation through digital transformation, we hope to have a better understanding of what makes a patient’s journey unique so that we can provide personalised and differentiated medicine in a sustainable way.”

The latest partnership builds on an already existing one on Covid-19.

UCB’s medicinal and computational chemists, as part of the previous worldwide open-science COVID Moonshot project, have provided compound designs to develop an orally bioavailable anti-viral for Covid-19. The highly potent ones emerged from UCB designs.

Combining science, computing power and AI algorithms could expedite the iteration cycles needed for analysing a vast chemical space to test several hypotheses and detect molecules that are more effective.

The companies intend to extend this model and detect additional areas where computing power, AI and science can fast-track the development of treatments for immunological and neurological diseases.

Microsoft Global Sales Marketing and Operations executive vice-president and president Jean-Philippe Courtois said: “With the deep knowledge that UCB offers in drug discovery and the knowledge of human biology, together with Microsoft’s unmatched expertise in computer science and AI, we have a unique opportunity to reinvent the way new medicines are created.”

Last July, Roche and Genentech agreed to a global, exclusive licence agreement with UCB to develop and commercialise an antibody treatment, UCB0107, for Alzheimer’s disease (AD).

Previous Post

Egyptian Drug Authority approves Sputnik V vaccine for emergency use

Next Post

Sinovac's Covid-19 vaccine gets approval in Thailand for emergency use

Related Posts

Peli BioThermal Announces Latest Distributor Partnerships
News

Peli BioThermal Announces Latest Distributor Partnerships

3rd March 2021
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22
Clinical Trials

Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

3rd March 2021
U.S. FDA confirms Pfizer COVID vaccine safe & effective
News

Merck to Help Produce Johnson & Johnson’s COVID-19 Vaccine

3rd March 2021
NovalGen Enters Strategic Partnership with HALIX B.V. to Manufacture Clinical Trial Materials
News

NovalGen Enters Strategic Partnership with HALIX B.V. to Manufacture Clinical Trial Materials

3rd March 2021
DHL expands pharma capabilities in South Africa
News

DHL Express partners with MASkargo to deliver first batch of Covid-19 vaccines to Malaysia

3rd March 2021
Full service: the expertise and efficiency of a one-stop shop
Drug Development

Full service: the expertise and efficiency of a one-stop shop

26th February 2021
Next Post
FSD Pharma Gets Go Ahead for Phase IIa COVID-19 Trial

Sinovac's Covid-19 vaccine gets approval in Thailand for emergency use

Latest News

Aptar Pharma and Noble Partner with dne pharma, a European Leader in Addiction Medicine, on Ventizolve Nasal Naloxone Treatment
Press Statements

Aptar Pharma and Noble Partner with dne pharma, a European Leader in Addiction Medicine, on Ventizolve Nasal Naloxone Treatment

16th March 2021
Peli BioThermal Announces Latest Distributor Partnerships
News

Peli BioThermal Announces Latest Distributor Partnerships

3rd March 2021
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22
Clinical Trials

Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

3rd March 2021
U.S. FDA confirms Pfizer COVID vaccine safe & effective
News

Merck to Help Produce Johnson & Johnson’s COVID-19 Vaccine

3rd March 2021
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
Press Statements

Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use

3rd March 2021
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In